The FDA released a much-anticipated draft guidance on how makers of rare disease genetic medicines can leverage a platform ...
Phase III data show the Braftovi regimen significantly improves overall survival and response versus chemo as a frontline treatment for advanced tumors.
NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...
Regenxbio and the trustees of UPenn in 2020 filed a patent infringement lawsuit alleging Sarepta was illegally using patented tech in its Duchenne gene therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results